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Abstract
Background: Endothelial colony-forming cells (ECFCs), are circulating endothelial progenitor cells increasingly studied in
various diseases because of their potential for clinical translation. Experimental procedures for their ex vivo culture still lack
standardization. In particular two different extracellular matrix proteins, either fibronectin or collagen, are commonly used
by different Authors for coating plastic plates, both allowing to obtain cells that have all the features of ECFCs. However,
possible differences in the impact of each substrate on ECFCs have not been analysed, so far. Therefore, in this study we
investigated whether fibronectin and collagen may differentially affect ECFC cultures.
Methodology/Principal Findings: ECFCs were isolated and cultured from peripheral blood mononuclear cells of healthy
donors. The impact of fibronectin compared with collagen as the only variable of the experimental procedure was analysed
separately in the phase of isolation of ECFC colonies and in the following phase of cell expansion. In the isolation phase,
although similar frequencies of colonies were obtained on the two substrates, ECFC colonies appeared some days earlier
when mononuclear cells were seeded on fibronectin rather than collagen. In the expansion phase, ECFCs cultured on
collagen showed a longer lifespan and higher cell yields compared with ECFCs cultured on fibronectin, possibly related to
the higher levels of IL-6 and IL-8 measured in their supernatants. ECFCs cultured on both substrates showed similar
immunophenotype and ability for in vitro tube formation.
Conclusions/Significance: Overall, the results of this study indicate that, although both fibronectin and collagen efficiently
sustain ECFC cultures, each of them brings some advantages within individual steps of the entire process. We suggest that
colony isolation performed on fibronectin followed by cell expansion performed on collagen may represent a novel and the
most efficient strategy to obtain ECFCs from adult peripheral blood samples.
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Introduction
Endothelial progenitor cells (EPCs) are bone marrow-derived
cells playing a critical role in adult vasculogenesis and endothelial
homeostasis [1,2]. Similar to embryonal angioblasts, EPCs are
recruited from the bone marrow to sites of endothelial injury,
where they contribute to blood vessel formation and repair
through their ability to proliferate, differentiate into mature
endothelial cells, integrate into the endothelial wall and produce
proangiogenic cytokines [3–5]. EPCs have stimulated considerable
interest in recent years due to the observation that variations in
their number and function are associated with many pathological
conditions, mainly cardiovascular diseases and cancer [6–12]. The
behaviour of EPCs during particular physiologic challenges are
under intense investigation as well, to better understand the role
and function of these cells in human physiology [9,13,14].
Moreover, EPCs are being studied for their role in maintaining
the integrity of endogenous endothelium and their regenerative
potential, with studies indicating the beneficial effect of EPC-based
cell therapies in both animal models and human diseases [15,16].
Circulating EPCs can be studied following two main approaches
[17]. One approach consists in identifying and selecting EPCs by
cell surface phenotype using fluorescently labeled antibodies and
flow cytometry directly performed on peripheral blood samples.
Key advantages of this strategy reside in need for very small blood
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e66734
samples, rapidity of execution and providing results that more
directly reflect the in vivo situation, compared with other methods
that investigate EPCs from blood samples after in vitro adhesion
and growth. The second approach consists in isolating and
expanding EPCs in vitro, starting from peripheral blood samples.
Compared with the first approach, this strategy offers the
advantage to allow more detailed cell characterization and obtain
cells in sufficient numbers to be used in animal experimental
models and in possible EPC-based cell therapies.
Among populations of putative EPCs that can be isolated and
cultured from adult blood, only endothelial colony-forming cells
(ECFCs), also called late-EPCs or outgrowth endothelial cells, are
considered the true EPCs. In fact, they have all the characteristics
of true endothelial progenitors, as they possess clonal proliferative
potential and they express endothelial but not hematopoietic cell
surface antigens. Most important, unlike other putative EPCs that
are endowed with proangiogenic activity but fail to display
vasculogenic activity, ECFCs have the unique ability to display in
vivo vasculogenic activity when implanted into immunodeficient
mice [18,19]. Because of the potential for clinical translation,
ECFCs isolated and propagated from peripheral blood are a
promising cell source for many applications including extensive
characterization in an increasing number of diseases, as well as in
vivo vasculogenesis and regenerative medicine.
Procedures for ECFC isolation and propagation strictly depend
on coating the culture surface with extracellular matrix protein
that promotes cell adhesion and growth [20]. In particular, either
fibronectin [21–26] or collagen [27–32] are commonly used as cell
culture substrates by different research groups to successfully
isolate and propagate cells that fulfill the criteria to be defined
ECFCs. However, possible differences in the impact of each
substrate on ECFC cultures have not been analysed, so far.
Therefore, in this study we investigated whether fibronectin and
collagen may differentially affect ECFC culture. To this aim, we
directly compared the effects of fibronectin and collagen, analysing
separately the two phases of the entire process: the phase of
isolation of ECFC colonies and the subsequent phase of ECFC cell
expansion. In this way, we could demonstrate advantages of each
substrate within individual steps of ECFC culture, and suggest that
the sequential use of both substrates may represent a novel and the




Ethics approval was obtained from the Institutional Review
Board of Istituto Clinico Humanitas, Rozzano, Milan, Italy, and
written informed consent was provided by study participants.
Isolation and culture of ECFCs
ECFCs were isolated and cultured from peripheral blood
mononuclear cells (PBMCs) of healthy donors according to
methods previously described [33], with some modifications.
Briefly, PBMCs obtained by Ficoll density gradient centrifugation
(Cedarlane, Hornby, Canada) were resuspended in EGM-2
medium (Cambrex Bio Science, Walkersville, MD) and seeded
onto 24-well tissue culture plates (56106 cells/well) precoated with
either human fibronectin (1 mg/cm2, Sigma-Aldrich, St. Louis,
MO) or type I rat-tail collagen (5 mg/cm2, BD Biosciences, San
Jose, CA), as indicated. After one day of culture, nonadherent cells
and debris were aspirated, adherent cells were washed with EGM-
2 medium, and EGM-2 medium was added to each well. Medium
was changed every 2 days until the first passage. The initial
appearance of visible colonies, identified as well circumscribed
monolayers of cobblestone-like cells, was determined by daily
culture observation using an inverted microscope, and the first day
of ECFC colony emergence was recorded. Colony size was
determined by measuring colony diameters 3 days after colony
appearance. The frequency of ECFC colonies was determined by
measuring the number of colonies in the primary culture on day
30, as no ECFC colony emerged at a later time point. ECFC
colonies were released from the original tissue culture plates by
trypsinization (trypsin 0.25%) (Euroclone, Wetherby, UK),
resuspended in EGM-2 medium, and plated onto 6-well tissue
culture plates precoated with fibronectin or collagen, as indicated.
Subconfluent cells were further subpassaged in flasks and
expanded until cell senescence, as determined by morphology
changes, decrease in proliferation and positive staining for
senescence-associated ß-galactosidase (BioVision Reasearch Prod-
ucts, Mountain View, CA) [34]. At each passage, viable cell counts
were obtained using a hemacytometer and trypan blue exclusion,
and cell-free culture supernatants were filtered and stored at –
20uC.
ECFC proliferation assay
Cell proliferation of ECFCs was assessed as described elsewhere
[35], with some modifications. Briefly, after 16 h of serum and
growth factor privation, ECFCs were incubated for 48 h in EGM-
2 medium, supplemented with rhIL-6 and/or rhIL-8 (Peprotech,
London, UK), as indicated. In inhibition experiments, neutralizing
anti-IL-6 and anti-IL-8 mAbs (R&D Systems, Minneapolis, MN)
were added 30 minutes before starting 48 h incubation with
complete medium and serum. The concentrations of mAbs were
chosen according to the Manufacturer’s instructions. Proliferation
was examined after 48 h by the colorimetric Crystal Violet (CV)
assay, as described elsewhere [36] with some modifications.
Briefly, the cells were fixed with 4% paraformaldehyde and
incubated in 0.1% CV for 20 min at room temperature. Excess
dye was removed by three brief rinses with double-distilled water,
the plates were air dried, and the dye was extracted with 10%
acetic acid, which was then read in a plate reader at 550 nm.
Cytokine measurement in ECFC supernatants
The amount of vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (bFGF), IL-6 and IL-8 in culture
supernatants were determined by DuoSet ELISA kits from R&D
Systems. All individual steps were performed according to the
manufacturer’s instructions.
Immunophenotyping of ECFCs
Immunophenotyping of ECFCs was performed as previously
described [33]. For antigen detection by flow cytometry, FITC-,
PE-, or PerCP-Cy5.5-conjugated monoclonal antibodies directed
against anti-human CD14, CD31 (Becton-Dickinson); CD45 (e-
Bioscience); VEGF receptor-2 (VEGFR-2) (R&D Systems); CD54,
CD144 (Serotec); CD146 (Biocytex) were used. Isotype-matched
irrelevant mAbs were used as negative controls. Data were
acquired on a FACSCanto flow cytometer (Becton-Dickinson) and
analysed using FlowJo 9.6.2 software (Tristar, Ashland, OR). Cells
were electronically gated according to light scatter properties to
exclude cell debris.
Uptake of Dil-acetylated low-density lipoprotein and
staining for Ulex Europeus lectin
The uptake of Dil-acetylated low-density lipoprotein (Dil-ac-
LDL) by ECFCs and their staining for Ulex Europaeus Agglutinin-
Effects of Fibronectin and Collagen on ECFCs
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Figure 1. Effects of fibronectin and collagen on isolation of ECFC colonies. Fibronectin promoted the appearance of ECFC colonies earlier
than collagen. (A) PBMCs from 9 donors were seeded on fibronectin-coated plates and PBMCs from other 9 donors were seeded on collagen-coated
plates; ECFC colonies from PBMCs seeded on fibronectin (white bar) appeared earlier than those seeded on collagen (gray bar). p value calculated by
the Mann-Whitney U-test. (B) PBMCs from 8 donors were divided into portions, with half of them seeded on fibronectin-coated plates and the rest
seeded on collagen-coated plates; also in these paired experiments ECFC colonies from PBMCs seeded on fibronectin (white circles) appeared earlier
than those seeded on collagen (gray circles). p value calculated by the Wilcoxon signed-rank test.
doi:10.1371/journal.pone.0066734.g001
Figure 2. Effects of fibronectin and collagen on ECFC cell expansion. Collagen sustained cell expansion of ECFCs more efficiently than
fibronectin. 14 ECFC colonies were divided into portions, with half of them seeded on fibronectin-coated plates and the rest seeded on collagen-
coated plates. (A) Representative phase-contrast photographs showing that ECFCs expanded on fibronectin and collagen formed similar
cobblestone-like monolayers with endothelial-like morphology. Photographs were obtained using an Olympus inverted microscope IX51, x10
magnification. ECFCs cultured on collagen (gray bar) compared with fibronectin (white bar) achieved (B) higher number of passages, (C) longer
lifespan and (D) higher cell yields. p values calculated by the Wilcoxon signed-rank test.
doi:10.1371/journal.pone.0066734.g002
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1 (UEA-1) were assessed as previously described [33]. Briefly,
ECFCs were cultured onto fibronectin- or collagen-coated, 2-
chamber Lab-Tek slides (Nalge NUNC International, Rochester,
NY) and attached cells were incubated with 10 mg/ml Dil-ac-LDL
(Molecular Probes, Eugene, OR) in EGM-2 medium for 1 hour at
37uC. Cells were then fixed with 2% formaldehyde for 10 minutes
and incubated for 1 hour with FITC-labeled UEA-1 (Sigma-
Aldrich). Slides were mounted in anti-fading mounting media
containing DAPI (Vectashield; Vector Laboratories, Burlingame,
CA) and analysed with an Olympus Fluoview FV1000 laser
scanning confocal microscope.
Matrigel capillary tube formation assay
Matrigel assays were performed as previously described [33].
Briefly, ECFCs were seeded onto 96-well tissue culture plates
coated with 70 ml Matrigel (Becton-Dickinson) at a cell density of
26104 cells per well, and incubated at 37uC. Cells were observed
during the following 12–72 hours with inverted microscopy for
capillary-like formation.
Statistical analysis
Data were shown as mean6 standard error of the mean (SEM).
Comparisons of samples to establish the statistical significance of
difference were determined by the Mann-Whitney U-test or
Wilcoxon signed-rank test, as indicated. All statistical analyses
assumed a 2-sided significance level of 0.05. Data analyses were
performed with Openstat software.
Results
Fibronectin as a substrate promotes the appearance of
ECFC colonies earlier than collagen
To assess whether the use of fibronectin rather than collagen as
a substrate may differently affect the efficiency of isolation of
ECFC colonies from peripheral blood, we compared the
appearance of ECFC colonies obtained after PBMC seeding on
either substrate. To this aim, we isolated PBMCs from 50 ml of
peripheral venous blood from 18 healthy donors (9 men, 9 women;
mean age 3463 years). PBMCs from 9 donors were then seeded
on fibronectin-coated plates and PBMCs from the other 9 donors
were seeded on collagen-coated plates. A similar number of
Figure 3. Effects of fibronectin and collagen on cytokine production by ECFCs. ECFCs expanded on collagen produced higher levels of IL-6
and IL-8 that ECFCs expanded on fibronectin. (A) Representative curves showing that the concentration of IL-6 and IL-8 in the supernatants of ECFCs
expanded on fibronectin (white circles) and collagen (gray circles) tended to increase with increasing passages. (B) ECFCs expanded on collagen (gray
bars) reached higher levels of IL-6 and IL-8, but not bFGF, than ECFCs cultured on fibronectin (white bars). The mean 6 SEM of the highest cytokine
concentration reached during culture of the same 14 ECFC colonies reported in Figure 2 is shown. p values calculated by the Wilcoxon signed-rank
test.
doi:10.1371/journal.pone.0066734.g003
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PBMCs was seeded in each condition (fibronectin: 69.269.56106
PBMCs vs collagen: 66.866.6, p = ns). As expected, colonies with
cobblestone-like morphology appeared on both extracellular
matrix protein substrates. At least one colony was obtained in 7
of 9 donors in both conditions, and similar frequencies of ECFC
colonies were obtained on the two substrates (fibronectin: 3.561.1
colonies/108 seeded PBMCs vs collagen: 3.360.7, p = ns).
However, ECFC colonies from donors whose PBMCs were
seeded on fibronectin appeared some days earlier than those
seeded on collagen (16.661.7 days vs 23.161.4, p = 0.009) (Figure
1A).
To subtract possible bias due to interindividual variability, we
repeated the same experiments comparing the influence of
fibronectin and collagen on the efficiency of ECFC colony
isolation starting from PBMCs obtained from a same donor. To
this aim, we isolated PBMCs from 100 ml of peripheral venous
blood from 8 healthy donors (4 men, 4 women; mean age 3163
years). PBMCs from the same donor were divided into portions,
with half of them seeded on fibronectin-coated plates and the rest
seeded on collagen-coated plates. A mean of 75.069.26106
PBMCs were seeded in each condition. Also in these paired
experiments, no difference was observed in the quantity of ECFC
colonies obtained with the two substrates. In fact, at least one
colony was obtained from all donors in both conditions, and the
frequency of ECFC colonies did not differ between substrates
(fibronectin: 3.060.6 colonies/108 seeded PBMCs vs collagen:
3.560.9, p = ns). Similarly to what we observed in the unpaired
experiments, also in these paired experiments ECFC colonies
appeared few days earlier when PBMCs were seeded on
fibronectin rather than collagen (19.461.3 days vs 22.561.3,
p = 0.009) (Figure 1B). Once established, ECFC colonies obtained
on both fibronectin and collagen increased rapidly in size,
indicating a high proliferation rate. No differences were observed
in colony size depending on the culture substrate.
Collagen as a substrate sustains ECFC cell expansion
more efficiently than fibronectin
We further asked whether the use of fibronectin rather than
collagen as a culture substrate may differently affect the efficiency
of cell expansion of ECFCs. To address this question, we
compared the behaviour of ECFCs cultured on either substrate.
To overcome the variability of cell growth rate commonly
observed among different ECFC colonies, we selected 14 colonies
isolated on fibronectin or collagen and, after their initial expansion
to form an endothelial monolayer, we divided them into portions,
with half of them seeded on fibronectin-coated plates and the rest
seeded on collagen-coated plates. Independently from the
substrate used for colony isolation, ECFCs cultured on both
substrates underwent cell proliferation and could be serially
Figure 4. Effects of IL-6 and IL-8 on ECFC proliferation. IL-6 and IL-8 may account, at least in part, for the higher cell proliferation of ECFCs
cultured on collagen as compared to fibronectin. Cell proliferation was assessed by the colorimetric CV assay, and expressed as OD. (A) Addition of IL-
6 or IL-8 to ECFCs cultured on fibronectin increased cell proliferation in a dose-dependent manner. The mean 6 SEM of 7 ECFC cultures is shown.
*p = 0.046 and **p = 0.009 compared with untreated ECFCs cultured on fibronectin, as calculated by the Wilcoxon signed-rank test. (B) Addition of IL-
6 and IL-8 together in the same culture did not further increase cell proliferation. One representative of three experiments is shown. (C) Addition of
neutralizing anti-IL-6 or anti-IL-8 mAb to ECFCs cultured on collagen induced a dose-dependent reduction of cell proliferation. One representative of
three experiments is shown.
doi:10.1371/journal.pone.0066734.g004
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passaged. During the passages the cells retained their endothelial-
like morphology, forming cobblestone-like monolayers that were
similar in the two culture conditions (Figure 2A). On both
substrates ECFCs showed a finite replicative lifespan and could be
passaged in some case up to passage 11 over a period of up to 70
days. However, ECFCs cultured on collagen achieved a signifi-
cantly higher number of passages (7.260.6 vs 6.660.6, p= 0.045)
(Figure 2B) and showed a longer lifespan before undergoing cell
senescence (47.264.9 days vs 40.064.8, p = 0.032) (Figure 2C),
compared with ECFCs cultured on fibronectin. More importantly,
higher cell yields were obtained at the end of the culture when
ECFCs were cultured on collagen rather than fibronectin (7.16108
cells vs 2.56108, p = 0.037) (Figure 2D).
Cytokines produced by ECFCs may contribute to the
increased cell expansion of ECFCs cultured on collagen
To investigate the mechanisms possibly involved in sustaining
the higher cell yield observed when ECFCs were cultured on
collagen rather than fibronectin, we analysed in our cultures the
main proangiogenic cytokines secreted by endothelial progenitor
cells [37]. To this aim, we measured the levels of VEGF, bFGF,
IL-6 and IL-8 in the supernatants recovered from each ECFC
culture just before cell passaging. VEGF was undetectable at any
passage in ECFC cultures expanded on any substrate, in
accordance with a previous study [38]. Representative curves of
the other cytokines measured during ECFC cultures are reported
in Figure 3A, showing that the concentration of IL-6 and IL-8, but
not bFGF, tended to increase with increasing passages and to be
higher in ECFC cultures expanded on collagen. The comparison
of the maximum levels of cytokines reached in the supernatants
during ECFC culture further indicated that the levels of IL-6 and
IL-8 were higher in ECFC cultures expanded on collagen rather
than fibronectin (collagen vs fibronectin, IL-6: 18706384 pg/ml
vs 12876276, p = 0.042; IL-8: 1902964153 pg/ml vs
1291662458, p = 0.039), while the levels of bFGF were similar
in the two conditions (269624 pg/ml vs 243669, p = n.s.) (Figure
3B).
To further assess whether IL-6 and IL-8 were responsible
indeed for the difference in ECFC expansion observed on different
substrates, we investigated whether addition of these cytokines to
ECFCs cultured on fibronectin could recapitulate the behaviour of
ECFCs cultured on collagen. To this aim we analysed the effects of
IL-6 and IL-8, added at concentrations similar to those measured
in culture supernatants, on ECFC proliferation. Cell proliferation
Figure 5. Effects of fibronectin and collagen on the immunophenotype of ECFCs. ECFCs expanded on fibronectin or collagen showed a
similar immunophenotype. On the left are reported flow cytometric histograms showing that, independently from the substrate used for cell culture,
ECFCs did not express CD45 and CD14, while they expressed at similar levels CD31, VEGFR2, CD144, CD146, CD54 and CXCR4. On the right are
reported immunofluorescence photographs showing that ECFCs expanded on both substrates incorporated Dil-ac-LDL and bound lectin UEA-1.
Photographs were obtained using an an Olympus Fluoview FV1000 confocal microscope, x40 magnification. One of three representative experiments
is reported.
doi:10.1371/journal.pone.0066734.g005
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was assessed by the colorimetric CV assay, and expressed as
optical density (OD). As shown in Figure 4A, cell proliferation of
ECFCs cultured on collagen was significantly higher than
proliferation of ECFCs cultured on fibronectin, as expected. Both
IL-6 and IL-8 added to ECFCs cultured on fibronectin induced a
significant and dose-dependent increase in cell proliferation,
inducing OD values similar to those of ECFCs cultured on
collagen. The addition of IL-6 and IL-8 together in the same
culture did not further increase cell proliferation (Figure 4B). To
further define the role of IL-6 and IL-8 in sustaining the higher
expansion of ECFCs on collagen, we performed inhibition
experiments with blocking antibodies. As shown in Figure 4C,
both anti-IL-6 and anti-IL-8 mAbs added to ECFCs cultured on
collagen induced a dose-dependent reduction of cell proliferation.
ECFCs expanded on fibronectin or collagen have similar
immunophenotype and ability for in vitro tubulogenesis
We then asked whether coating of culture plates with
fibronectin rather collagen as an extracellular matrix protein
may differently affect the immunophenotype or functional
properties of the expanded cells. To this aim, we compared early
passaged (3–5) ECFCs expanded on fibronectin with equally
passaged ECFCs expanded on collagen. As shown in Figure 5,
ECFCs cultured on both substrates had a comparable endothelial
phenotype. In particular, immunophenotyping by flow cytometry
revealed that in both cases ECFCs lacked the hematopoietic
markers CD45 and CD14 and expressed the endothelial cell
surface antigens CD31, VEGFR2, CD144, CD146, CD54 and
CXCR4 to a similar extent. Furthermore, ECFCs expanded on
both substrates incorporated Dil-ac-LDL and bound lectin UEA-
1.
As shown in Figure 6, the Matrigel capillary tube formation
assay demonstrated that ECFCs expanded on both substrates were
similarly able to form capillary-like structures in vitro.
Discussion
In this study, we provide evidence that fibronectin and collagen
used for culture surface coating differently affect the efficiency of
ECFC isolation and expansion. This is an important issue. In fact,
although ECFCs are increasingly being studied in various diseases
because of their potential for clinical translation, yet experimental
procedures for their ex vivo culture still lack standardization. In
particular, either fibronectin or collagen are commonly used as
coating substrates to obtain cells that have all the features needed
to be defined ECFCs [21–32,39], without any evidence for
advantages of one substrate over the other. Our results clearly
confirmed that both substrates allow the isolation and expansion of
ECFCs with frequency of obtained colonies, cell growth rates, cell
yields and cell features similar to those reported by other Authors
[27,29,40–43]. However, by analysing the impact of fibronectin
compared with collagen as the only variable of the experimental
protocol, we could demonstrate that there were some differences
between substrates. Moreover, by analysing separately the phase of
isolation of ECFC colonies appearing from seeded PBMCs, and
the following phase of cell propagation of ECFCs, we could
demonstrate some advantages of the two substrates within
individual steps of the entire process.
The results obtained in the first step of the process indicated that
fibronectin sustained the isolation of ECFC colonies more
efficiently than collagen. In fact, maintaining constant all the
other experimental variables, PBMCs seeded on fibronectin gave
rise to ECFC colonies almost one week earlier than PBMCs
seeded on collagen. Notably, this advantage of fibronectin-coating
was confirmed in the experiments where the comparison between
substrates was performed within the same subject, thus overcom-
ing differences possibly due to interindividual variability. We
suggest that the shorter time of initial cluster appearance
supported by fibronectin may be advantageous, as it may help
reduce time-and reagent-consuming procedures in the lab and
may allow getting results faster.
On the other hand, the results obtained in the second step of the
process indicated that collagen sustained more efficiently than
fibronectin the cell propagation of ECFCs. In fact, the comparison
of parallel cell cultures, started from the same colony and
performed in identical experimental conditions apart from the
substrate used for plastic coating, demonstrated that higher cell
yields were obtained when ECFCs were cultured on collagen,
likely related to the longer survival of cell cultures and the higher
cell proliferation observed on this substrate. Notably, the
supernatants obtained from ECFCs cultured on collagen con-
tained higher levels of IL-6 and IL-8, angiogenic cytokines that
have been demonstrated to directly promote the survival of
endothelial cells, as well [39,44]. It may be possible that the higher
levels of IL-6 and IL-8 may derive from the higher cell yields and
longer lifespan of ECFCs cultured on collagen. However, the
results obtained in the experiments of cytokine supplementation
and blocking seem to support that IL-6 and IL-8 may account, at
least in part, for the differences in the expansion of ECFCs on the
different substrates. Apart from these differences in cytokine
production, our results clearly indicated that ECFCs expanded on
fibronectin and collagen shared similar ability for in vitro
tubulogenesis and similar phenotype. It is important to note that
Figure 6. Effects of fibronectin and collagen on the ability of
ECFCs for in vitro tubulogenesis. ECFCs expanded on fibronectin or
collagen showed a similar ability to form capillary-like structures in vitro.
Independently from the substrate used for cell culture, ECFCs cultured
in Matrigel gave rise within 12 hours of incubation to vascular
structures. Representative phase-contrast photographs showing that
the capillary-like structures formed by ECFCs cultured on fibronectin
and collagen were similar. Photographs were obtained using an
Olympus inverted microscope IX51, x4 magnification.
doi:10.1371/journal.pone.0066734.g006
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also CXCR4, receptor for stromal-derived cell factor-1 with a key
role in selective migration and recruitment of endothelial
progenitor cells into the sites of blood vessel formation and repair
[14,45], was similarly expressed on ECFCs cultured on the two
substrates. This is a crucial issue, because ECFCs are increasingly
used in studies of in vivo vasculogenesis, where the ability of these
cells to adequately localize into the sites of tissue injury is indeed a
crucial prerequisite. Notably, controversial results on the expres-
sion of CXCR4 by ECFCs have been reported, possibly related to
the source of PBMCs used for ECFC culture [26,46,47]. All
together, the results obtained analysing the expansion phase of
ECFC culture demonstrated that fibronectin and collagen allow
the propagation of ECFCs with very similar features. However,
the use of collagen may be advantageous as it permits to obtain a
higher number of cells to be used for subsequent experiments. An
additional advantage deriving from the use of collagen for plastic
coating in the expansion phase may be economic, as collagen is
about twenty times cheaper than fibronectin, and the consumption
of coating substrate during ECFC expansion may be huge.
We conclude from this study that, although both fibronectin
and collagen are appropriate to sustain the entire process of ECFC
culture, colony isolation on fibronectin followed by cell expansion
on collagen may represent the most efficient strategy to obtain
ECFCs from adult peripheral blood samples.
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